Нитроминт

Quick links to important sections

Нитроминт

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Нитроминт

Quick Facts

Property Description
Active ingredient Nitroglycerin (Glyceryl trinitrate, GTN)
Form Lingual spray, Sublingual tablets
Pharmacological class Nitrate Vasodilator / Antianginal Agent
Common use Rapid relief of acute circulatory discomfort
Origin Synthetic (Organic nitrate)

1. What Type of Medicine is Нитроминт?

Нитроминт (Nitromint) is a specific prescription medication defined by its potent active pharmaceutical ingredient, Nitroglycerin (Glyceryl trinitrate, GTN). It is formally classified as an Antianginal Agent and a Nitrate Vasodilator, placing it within the category of drugs utilized for acute management of issues related to heart blood flow. Nitroglycerin acts as a quick-onset antianginal agent through its effect on blood vessels. This classification confirms the medicine is specifically designed to work quickly to ease cardiac-related discomfort by addressing imbalances between the heart's oxygen supply and demand.

2. Composition and Available Forms of Нитроминт

The core substance within Нитроминт, Nitroglycerin, is a potent, synthetic compound belonging to the organic nitrate chemical family. The medication is commonly supplied in two principal fast-acting pharmaceutical forms: a lingual spray and sublingual tablets. These preparations are designed for rapid absorption via the oral mucosa, making it a single-ingredient product optimized for quick onset. The immediate-acting forms of nitroglycerin are recognized for providing acute relief by rapidly reducing cardiac strain. This highlights that the rapid-acting design is critical for the medicine's effectiveness when quick relief is needed. The composition typically involves the active ingredient dissolved in an alcoholic solution for the spray, or compounded with pharmaceutical excipients for the tablet form.

3. General Principle: Why is Vasodilation Important for the Heart?

The general therapeutic purpose of Нитроминт relies entirely on its ability to induce rapid and profound vasodilation, which is the relaxation and widening of blood vessels. This action is crucial because it immediately reduces the volume of blood returning to the heart (preload) and decreases the resistance the heart must pump against (afterload). By lessening the heart's workload in this manner, the medication swiftly helps to alleviate the acute strain on the cardiac muscle, providing prompt relief associated with insufficient blood flow, such as during a temporary episode of chest discomfort.

Regulatory References

  1. Nitroglycerin - StatPearls - NCBI Bookshelf - NIH
  2. Label: NITROGLYCERIN tablet - DailyMed

What side effects are possible with Нитроминт?

Possible side effects and safety information

The official safety profile for Nitroglycerin (the active ingredient in Нитроминт) is structured around its potent vasodilatory action, which dictates the type and frequency of adverse reactions documented in regulatory sources.


Frequency-Classified Adverse Reactions

The most frequently documented side effects are categorized by regulatory agencies based on incidence:

Classification Examples of Reactions
Very Common Headache (often dose-related and throbbing)
Common Dizziness, Hypotension, Tachycardia, Facial Flushing, Nausea, Vomiting
Uncommon Syncope (fainting), Enhanced Angina Pectoris, Allergic skin reactions

These effects primarily involve the Nervous System Disorders (e.g., headache, dizziness) and Vascular Disorders (e.g., hypotension, flushing).

Serious Adverse Reactions and Restrictions

Official labels identify certain reactions and conditions of high safety concern:

  • Serious Adverse Reactions: The risk of Severe Hypotension and resultant Syncope (collapse) is documented, along with the potential for Methemoglobinemia in susceptible individuals or with high doses.
  • Time-Related Safety Patterns: Headache is typically most frequent at the start of therapy but generally lessens with continued use. The label also notes that nitrate tolerance may develop with excessive or long-term use.
  • Absolute Restrictions (Contraindications): The medicine is strictly forbidden for individuals with Severe Anemia, Increased Intracranial Pressure, or those currently using Phosphodiesterase-5 (PDE-5) Inhibitors (like sildenafil) or Soluble Guanylate Cyclase (sGC) Stimulators due to the risk of severe, life-threatening hypotension.

Population-Specific Considerations

Regulatory documentation notes that the safety and effectiveness of this medicine have not been established for pediatric use. For older adults, caution is advised due to a higher likelihood of age-related conditions affecting the liver, kidney, or heart, which may alter the safety profile.

Overdose and Emergency Response

The official regulatory documentation outlines specific manifestations and mandatory emergency actions for Nitroglycerin (Нитроминт) overdose, derived from its potent vasodilator effects.

Documented Overdose Manifestations

Overdose is primarily documented by symptoms related to excessive vasodilation, including severe hypotension, persistent throbbing headache, flushing, vertigo, and potential syncope. More serious manifestations listed in official labeling include circulatory collapse and shock.

A specific, life-threatening complication noted in regulatory texts is methemoglobinemia, a condition of impaired oxygen transport presenting with signs such as cyanosis.

Required Emergency Actions

Official regulatory labeling mandates that immediate medical attention must be sought at the first sign of a suspected overdose, and the drug should be discontinued immediately. Urgent medical intervention is required for any signs of profound hypotension or the onset of cyanosis.

Official Management Procedures

Management documented in official labeling is supportive and symptomatic. Procedures include placing the patient in a supine position with elevated extremities and using intravenous central volume expansion to counteract hypotension. Methylene blue is the documented specific treatment for clinically significant methemoglobinemia. Regulatory documents confirm that no specific antagonist to the primary vasodilator effects is known.

Therapeutic Uses of Нитроминт

What Нитроминт Treats: Main Uses and Benefits

This antianginal agent is commonly used in situations involving symptoms associated with acute or episodic changes of heart discomfort. The medication is commonly used to help with the acute relief or acute prophylaxis of angina pectoris due to coronary artery disease.

The therapeutic scope is considered relevant in conditions requiring short-term symptomatic assistance, including stable ischemic heart disease, acute coronary syndromes, and specific contexts of acute left ventricular failure. The core benefit lies in managing a sudden episode of symptoms that may become intense or disruptive, such as the sudden squeezing, pressure, or tightness in the chest.

This medication is commonly applied to manage acute symptomatic episodes or preventatively, applied in scenarios where the onset of symptoms is associated with physical demand. This preventative use supports the patient during anticipated physical demand and may assist with maintaining functional stability.

In clinical settings, it is considered relevant for providing additional symptomatic support in more severe acute conditions, contributing to easing the overall symptom load associated with acute circulatory discomfort.


Quick Fact: Relief for Acute Discomfort
Core Symptom Managed Squeezing, tightness, or pressure in the chest (Anginal pain)
Primary Use Context Management of acute symptomatic episodes or prophylactic application
Patient Benefit Contributes to easing the overall symptom load during acute discomfort

Regulatory References

  1. NIH DailyMed label for Nitroglycerin

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults with coronary artery disease requiring acute relief or acute prophylaxis of angina pectoris.
Populations for whom use is not recommended (if applicable) Pregnant women: Use only if clearly needed. Lactating women: Decision required to discontinue nursing or discontinue the drug.
Populations for whom use is contraindicated Patients with known hypersensitivity to nitroglycerin or other nitrates. Patients currently taking Phosphodiesterase Type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) or Soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat).
Age-related eligibility rules Pediatric Use (Under 18 years): Safety and effectiveness have not been established. Geriatric Use (65+ years): Use is permitted, but dose selection must be cautious due to age-related physiological changes.
Condition-specific eligibility rules Severe Anemia, Increased Intracranial Pressure, Acute Circulatory Failure or Shock, and certain obstructive heart conditions (e.g., hypertrophic cardiomyopathy, aortic/mitral stenosis) are contraindications.

Eligibility Classifications (High-Level)

Category Regulatory Status Definition (Official Terminology)
Eligibility severity classification (as defined in official documents) Contraindicated (Absolute prohibition); Not Established (Pediatric); Caution (Geriatric, Hypotensive, Volume-Depleted); Conditional Use (Pregnancy/Lactation).
Eligibility-context constraints (as defined in official documents) Constraint driven by concomitant drug use (PDE5/sGC inhibitors) and hemodynamic status (hypotension, circulatory failure).

Resulting Eligibility Structure

Official regulatory documents define who can and cannot use this medicine primarily by establishing absolute prohibitions based on co-medication and severe life-threatening clinical states (contraindications). For other groups, such as children, pregnant women, and the elderly, the profile defines eligibility as not established or requires caution due to a lack of sufficient data or an increased physiological risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation confirms that the interaction profile of Нитроминт (Nitroglycerin) is primarily characterized by the risk of additive vasodilatory effects.

Contraindicated Combinations

Co-administration with Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) is formally contraindicated. This absolute restriction is due to the potentiation of hypotensive effects, which risks severe low blood pressure.

Pharmacodynamic and Substance Interactions

Type of Interacting Agent Official Interaction Outcome
Other Antihypertensive Agents (e.g., Beta-Blockers, Calcium Channel Blockers, Phenothiazines) Risk of additive hypotensive effects or marked orthostatic hypotension.
Alcohol (Ethanol) May cause hypotension due to additive vasodilatory effects.
Aspirin (Acetylsalicylic acid) May enhance the vasodilatory and hemodynamic effects of Nitroglycerin.

Pharmacokinetic and Procedural Constraints

Oral administration of Nitroglycerin is documented to decrease the first-pass metabolism of Dihydroergotamine, resulting in increased oral exposure to that co-administered medicine. Furthermore, the label notes that intravenous Nitroglycerin reduces the anticoagulant effect of Heparin; while this is primarily relevant to the intravenous form, it establishes a procedural monitoring constraint for this interaction.

Mechanism of Action

The pharmacological action of Нитроминт (Nitroglycerin) initiates when the drug, acting as a prodrug, is converted by the enzyme mitochondrial aldehyde dehydrogenase 2 ( mtALDH2) within vascular smooth muscle cells. This bioactivation releases the active signaling molecule, Nitric Oxide (NO). NO then binds to and stimulates soluble Guanylate Cyclase (sGC), which increases the production of the intracellular messenger cyclic GMP (cGMP), initiating a cascade that leads to smooth muscle relaxation. This vasodilatory effect is most significant in the venous circulation, leading to a marked increase in venous capacitance (venous pooling). The resultant shift in hemodynamics reduces the volume of blood returning to the heart (preload), subsequently lowering ventricular filling pressure and decreasing myocardial wall tension. The mechanism is subject to limitation: repeated exposure can saturate or deplete the mtALDH2 enzyme, leading to a reduced physiological response known as tachyphylaxis (tolerance).

Dosage and Administration Information

Official Administration Guidelines

Нитроминт (Nitromint) is a metered-dose sublingual spray, typically containing 400 mu g of nitroglycerin per actuation, that must be used according to professional medical instructions. The administration procedure is highly specific to ensure proper delivery through the oromucosal route.

Procedural and Dosing Rules

Usage Constraint Official Instruction
Route Applied onto or under the tongue; must not be inhaled or swallowed.
Preparation Before first use, or if unused for several weeks, the pump must be primed with test sprays until a fine mist is observed. The container should not be shaken.
Acute Dosing The standard dose is 1 or 2 metered sprays at the onset of an acute episode. The patient should preferably be in a sitting position during application.
Repeat Dosing A dose may be repeated every 5 minutes, if needed.
Maximum Limit No more than 3 metered sprays should be administered within a 15-minute period. If pain persists after the third dose, immediate medical attention is required.

Population and Special Conditions

No dose adjustment is typically required for elderly patients. Usage is not recommended for children or adolescents under 18 years of age. For prophylactic use, the recommended dose is administered 5 to 10 minutes prior to engaging in an activity that is known to precipitate an event. The mouth must be closed immediately after each administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Нитроминт

Evidence for Acute Relief and Prevention of Angina Pectoris

Нитроминт (fast-acting nitroglycerin) was studied for its relevance to the acute management of chest discomfort, a condition characterized by fluctuating or episodic manifestations. Researchers primarily used short-term, randomized controlled trials (RCTs), often designed as crossover studies, to explore short-term symptom changes in a controlled environment. The populations evaluated were mainly adult patients diagnosed with chronic stable angina pectoris due to known coronary artery disease.

Research highlights changes measured during the study period by focusing on functional endpoints and symptom endpoints. For instance, studies examined the time it takes for acute chest discomfort to resolve, which is an outcome related to physical discomfort. Findings describe the patterns of measured outcomes related to symptom timing and functional capacity observed under the specific conditions of the trial.

Evidence for Symptomatic Support in Acute Ischemic Events

Research has also explored the observation of the medication in acute care settings, applied in research contexts involving fluctuating or unstable symptoms, such as the initial phases of acute coronary syndromes. These studies were conducted during periods of increased symptom activity and often involved comparisons to intravenous (IV) formulations. In these contexts, studies monitored outcomes capturing phases of heightened symptom activity, such as the incidence of recurrent or refractory ischemia (episodes where symptoms became more noticeable).

Long-Term Evidence and Follow-up Durations

The evidence base for fast-acting nitroglycerin formulations is focused primarily on short-term outcomes. The follow-up durations were limited, often measured in minutes, hours, or days, as this is relevant to the medicine's focus on rapid symptomatic relief research. Studies of extended duration concerning major clinical outcomes, such as mortality or heart attack, are not fully established for the acute-acting forms. This means that research provides context but not individual predictions regarding long-term functional outcomes.

What Remains Uncertain About the Research

Research highlights what is known—and what is still uncertain—about this medicine. A key limitation noted in the research is that tolerance was observed. This means that studies have explored the phenomenon where the response pattern appears to lessen when the medicine is used very frequently over time. Additionally, comparative evidence against all other therapeutic options is often lacking in the existing acute-use research. Research does not determine whether an individual will experience observed group patterns outside of the specific conditions under which the studies were conducted.

Key Studies & References Nitroglycerin in ACLS (Advanced Cardiovascular Life Support) for acute ischemic chest pain

Frequently Asked Questions (FAQ)

Common questions about Нитроминт (FAQ)


Q: Is it normal to feel a tingling or burning sensation under the tongue after using Нитроминт?

A: Official information indicates that a temporary tingling or burning sensation under the tongue may occur after using the spray. While regulatory documents list similar sensations as a potential side effect, the presence of a tingling or burning sensation is often interpreted by patients as a sign that the medication is actively being absorbed.


Q: Does Нитроминт expire, and how should I store it?

A: Like all prescription medications, Нитроминт has an expiration date printed on the packaging, and for legal and safety reasons, medications should not be used past this date, as potency is no longer guaranteed. The medication must be stored at Controlled Room Temperature (20°C to 25°C) and kept strictly away from heat, open flames, and ignition sources.


Q: Is Нитроминт addictive or habit-forming?

A: Official drug labels for the active ingredient do not indicate that it has abuse or addictive potential. However, regulatory documents do note that a phenomenon called tolerance (tachyphylaxis) can develop with frequent or prolonged use, where the body's response to the drug may become less pronounced over time.


Q: What are the signs of an allergic reaction to Нитроминт?

A: Signs of a serious allergic reaction, which are rare, are documented in regulatory sources and include difficulty breathing (trouble breathing or wheezing) and swelling of the face, lips, tongue, or throat. Official guidance indicates that if these symptoms occur, immediate medical help is necessary.


Q: Can I carry Нитроминт in my pocket or bag all the time?

A: Regulatory storage instructions require the medicine to be kept in its original container and maintained at Controlled Room Temperature. Carrying the spray should be done in a way that minimizes exposure to temperatures outside of the recommended range, as regulatory guidelines prioritize maintaining product stability.


Q: Can I use Нитроминт as a preventative measure before exercise?

A: Official product information states that it can be administered preventatively, usually 5 to 10 minutes prior to engaging in activities known to precipitate an acute episode of chest discomfort.


Q: What is the shelf life of an unopened bottle of Нитроминт?

A: The expiration date printed on the outer packaging indicates the period for which the manufacturer guarantees the product's full strength and quality. The unopened bottle should be stored under the recommended conditions until this date.


Q: Are there generic versions of Нитроминт available?

A: Yes, regulatory databases list various generic preparations of nitroglycerin lingual aerosol or spray. These generics contain the same active ingredient and are approved by regulatory bodies to work the same way as the brand-name product.


Q: Does the efficacy of Нитроминт change in hot or cold weather?

A: The official product information specifies that the medicine must be stored at a Controlled Room Temperature for its stability and effectiveness to be guaranteed. Exposure to temperatures outside of the specified storage range may potentially affect the drug's intended function or stability.


Q: What are the serious but rare side effects of Нитроминт?

A: Serious, but uncommon, adverse reactions documented in the official label include conditions such as severe hypotension (very low blood pressure), syncope (fainting), and methemoglobinemia in susceptible individuals.


Q: Can the spray bottle of Нитроминт be damaged by dropping it?

A: Official handling guidelines caution against forceful actions like piercing or burning the container. Since the spray relies on a precise metering pump, physical damage from dropping may compromise the integrity of the device and its ability to deliver the correct dose.


Q: Is a metallic taste in the mouth after using Нитроминт normal?

A: While specific mentions of a metallic taste are not consistently present across all regulatory labels, the official adverse reactions list sometimes includes an alteration of taste as a rare side effect. This may encompass unusual or metallic taste sensations.


Q: Can I travel by air with my Нитроминт spray?

A: As a prescription medication, it is generally permitted to be carried on flights. While generally permitted, checking guidelines from transportation authorities is advisable, and the user must be mindful of the required storage conditions and the warning to sit or rest immediately after administration.


Q: What should I avoid doing right after using Нитроминт?

A: One should avoid inhaling the spray, and caution is advised against standing up or moving too quickly immediately after use. This caution is advised to help reduce the risk of experiencing dizziness or fainting, which can occur due to the medicine’s effect on blood pressure.


Q: Is there a maximum number of sprays that can be used within an hour?

A: The acute dosing instructions define a limit of no more than three metered sprays within a 15-minute period for a single episode. Official guidance states that if symptoms persist after the third spray within the 15-minute period, it is important to seek immediate medical attention, as further use is outside the typical acute dosing regimen.

How should Нитроминт be stored and disposed of?

The storage and disposal of Nitromint (Nitroglycerin lingual spray) must adhere strictly to labeled regulatory requirements to maintain product stability and ensure safety, particularly due to the container's contents.

Storage Conditions

Requirement Type Official Regulatory Statement
Temperature Store at Controlled Room Temperature (20°C to 25°C, or 68°F to 77°F); do not freeze.
Handling Store away from heat, sparks, open flames, and ignition sources. Smoking is prohibited near the product.
Container Integrity Store in the original container. Do not forcefully open, pierce, or burn the container after use.
Stability The device remains adequately primed for six weeks after initial use. If unused for this period, it must be re-primed as per label instructions.
Child Safety Keep the medication in a safe place and out of the sight and reach of children.

Disposal

Unused or expired product must not be disposed of via household trash or wastewater. Consult a healthcare professional or pharmacist for proper disposal methods to comply with environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Нитроминт found in:

A-Z Index: